Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Substudy of Orenitram Dosing Transition (BID to TID)
NCT01934582Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Aug 2013
- Primary completion
- Nov 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Aug 2013; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01934582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01934582.